Albemarle（0HC7）株式概要アルベマール・コーポレーションは世界中にエネルギー貯蔵ソリューションを提供している。 詳細0HC7 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長4/6過去の実績0/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より52%で取引されている 収益は年間37.18%増加すると予測されています リスク分析過去3か月間に大規模なインサイダー売却が発生 UK市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る0HC7 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$169.3575.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1b9b2016201920222025202620282031Revenue US$7.6bEarnings US$711.1mAdvancedSet Fair ValueView all narrativesAlbemarle Corporation 競合他社Johnson MattheySymbol: LSE:JMATMarket cap: UK£3.5bCroda InternationalSymbol: LSE:CRDAMarket cap: UK£4.0bElementisSymbol: LSE:ELMMarket cap: UK£842.9mVictrexSymbol: LSE:VCTMarket cap: UK£531.2m価格と性能株価の高値、安値、推移の概要Albemarle過去の株価現在の株価US$169.3552週高値US$221.1052週安値US$53.83ベータ1.361ヶ月の変化-14.02%3ヶ月変化0.42%1年変化194.31%3年間の変化-17.13%5年間の変化1.35%IPOからの変化48.02%最新ニュースRecent Insider Transactions • 20hChairman recently sold US$3.0m worth of stockOn the 15th of May, Jerry Masters sold around 16k shares on-market at roughly US$184 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jerry has been a net seller over the last 12 months, reducing personal holdings by US$5.0m.Reported Earnings • May 12First quarter 2026 earnings released: EPS: US$2.35 (vs US$0.003 loss in 1Q 2025)First quarter 2026 results: EPS: US$2.35 (up from US$0.003 loss in 1Q 2025). Revenue: US$1.43b (up 33% from 1Q 2025). Net income: US$277.4m (up US$277.7m from 1Q 2025). Profit margin: 19% (up from 0% in 1Q 2025). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.お知らせ • May 07Albemarle Corporation announces Quarterly dividend, payable on July 01, 2026Albemarle Corporation announced Quarterly dividend of USD 0.4050 per share payable on July 01, 2026, ex-date on June 12, 2026 and record date on June 12, 2026.お知らせ • Apr 07Albemarle Corporation to Report Q1, 2026 Results on May 06, 2026Albemarle Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026お知らせ • Mar 25Albemarle Corporation Announces Director James O’Brien Will Not Stand for Re-Election, Effective May 5, 2026Albemarle Corporation announced James O’Brien, director will not stand for reelection. James O’Brien's directorship will end effective at the Annual Meeting to be held on May 5, 2026 pursuant to attained the age of 72 in 2026, and, accordingly, is not nominated for re-election at this annual meeting.お知らせ • Mar 12Albemarle Corporation, Annual General Meeting, May 05, 2026Albemarle Corporation, Annual General Meeting, May 05, 2026. Location: 4250 congress street north carolina 28209, charlotte, United States最新情報をもっと見るRecent updatesRecent Insider Transactions • 20hChairman recently sold US$3.0m worth of stockOn the 15th of May, Jerry Masters sold around 16k shares on-market at roughly US$184 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jerry has been a net seller over the last 12 months, reducing personal holdings by US$5.0m.Reported Earnings • May 12First quarter 2026 earnings released: EPS: US$2.35 (vs US$0.003 loss in 1Q 2025)First quarter 2026 results: EPS: US$2.35 (up from US$0.003 loss in 1Q 2025). Revenue: US$1.43b (up 33% from 1Q 2025). Net income: US$277.4m (up US$277.7m from 1Q 2025). Profit margin: 19% (up from 0% in 1Q 2025). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.お知らせ • May 07Albemarle Corporation announces Quarterly dividend, payable on July 01, 2026Albemarle Corporation announced Quarterly dividend of USD 0.4050 per share payable on July 01, 2026, ex-date on June 12, 2026 and record date on June 12, 2026.お知らせ • Apr 07Albemarle Corporation to Report Q1, 2026 Results on May 06, 2026Albemarle Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026お知らせ • Mar 25Albemarle Corporation Announces Director James O’Brien Will Not Stand for Re-Election, Effective May 5, 2026Albemarle Corporation announced James O’Brien, director will not stand for reelection. James O’Brien's directorship will end effective at the Annual Meeting to be held on May 5, 2026 pursuant to attained the age of 72 in 2026, and, accordingly, is not nominated for re-election at this annual meeting.お知らせ • Mar 12Albemarle Corporation, Annual General Meeting, May 05, 2026Albemarle Corporation, Annual General Meeting, May 05, 2026. Location: 4250 congress street north carolina 28209, charlotte, United Statesお知らせ • Mar 03+ 1 more updateKPS Capital Partners, LP completed the acquisition of 51% stake in Ketjen Corporation from Albemarle Corporation (NYSE:ALB).KPS Capital Partners, LP entered into a Stock Purchase Agreement to acquire Ketjen Corporation from Albemarle Corporation (NYSE:ALB) for $800 million on October 25, 2025. Under the terms of the Stock Purchase Agreement, Albemarle Corporation will sell 51% of the common stock of Ketjen (Purchased Shares) to KPS Capital Partners and contribute remaining 49% of common stock of Ketjen to Holdco, that was organized by and is affiliated with KPS Capital Partners LP. At the closing of the sale, contribution and other transactions contemplated by the Stock Purchase Agreement (collectively, the “Transaction”), Albemarle will receive an estimated $536 million in cash and will own common units of Holdco (the “Rollover Equity”). Under the Stock Purchase Agreement, the purchase price for the Purchased Shares is $800.0 million, less the value ascribed to the Contributed Shares pursuant to the terms and conditions of the Stock Purchase Agreement, and is further subject to adjustment for closing cash, indebtedness, net working capital and transaction expenses. Albemarle and KPS, through affiliates, will own approximately 49% and 51% of Ketjen at close, respectively, with KPS having a majority of the Board of Directors and operational control of Ketjen. The debt financing has been provided by Barclays, Jefferies, BNP Paribas and Santander. The termination fee of $32.5 million has to be paid by KPS Capital Partners, LP to Albemarle Corporation, if the closing has not occurred by April 30, 2026. The transactions is expected to be completed in the first half of 2026, with both subject to customary closing conditions and regulatory approvals, including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), as well as approvals from competition and foreign investment authorities from certain non-U.S. jurisdictions and certain other governmental authorities. Goldman Sachs & Co. LLC acted as financial advisor and K&L Gates LLP acted as legal advisor for Albemarle Corporation. Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor and Raymond James Financial, Inc. acted as financial advisor for KPS Capital Partners, LP. Roel Fluit, Michel van Agt, Guido Koop, and Vincent van der Lans of Loyens & Loeff acted as legal advisor to KPS Capital Partners. KPS Capital Partners, LP completed the acquisition of 51% stake in Ketjen Corporation from Albemarle Corporation (NYSE:ALB) on March 2, 2026. Albemarle will retain reamining 49% stake in Ketjen.お知らせ • Feb 27Albemarle Corp. Announces Quarterly Common Stock Dividend, Payable on April 1, 2026The Board of Directors of Albemarle Corporation announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable April 1, 2026, to shareholders of record at the close of business as of March 13, 2026.お知らせ • Feb 12+ 2 more updatesAlbemarle Corporation Provides Earnings Guidance for 2026Albemarle Corporation provided earnings guidance for 2026. For the period the company expects the Net sales of $5.7 billion to $6.0 billion. Sales volumes are expected to be approximately flat following inventory drawdowns that occurred in 2025.お知らせ • Jan 14Albemarle Corporation to Report Q4, 2025 Results on Feb 11, 2026Albemarle Corporation announced that they will report Q4, 2025 results After-Market on Feb 11, 2026お知らせ • Dec 13Albemarle Corporation Announces Resignation of Dean L. Seavers as Director, Effective December 12, 2025Albemarle Corporation announced that Dean L. Seavers tendered his resignation from the Board of Directors and all committees on which he serves, effective December 12, 2025.Upcoming Dividend • Dec 05Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 12 December 2025. Payment date: 02 January 2026. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (4.0%).Reported Earnings • Nov 06Third quarter 2025 earnings released: US$1.72 loss per share (vs US$9.45 loss in 3Q 2024)Third quarter 2025 results: US$1.72 loss per share (improved from US$9.45 loss in 3Q 2024). Revenue: US$1.31b (down 3.5% from 3Q 2024). Net loss: US$202.4m (loss narrowed 82% from 3Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.お知らせ • Nov 06+ 1 more updateAlbemarle Corporation Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2025Albemarle Corporation announced Goodwill impairment charges for the third quarter ended September 30, 2025. For the period, the company reported Goodwill impairment charges of $181,070,000.Declared Dividend • Nov 03Second quarter dividend of US$0.41 announcedDividend of US$0.41 is the same as last year. Ex-date: 12th December 2025 Payment date: 2nd January 2026 Dividend yield will be 1.6%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.お知らせ • Oct 28Albemarle Corp. Announces Quarterly Common Stock Dividend, Payable on January 2, 2026The Board of Directors of Albemarle Corp. announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable January 2, 2026, to shareholders of record at the close of business as of December 12, 2025.お知らせ • Sep 26Albemarle Corporation to Report Q3, 2025 Results on Nov 05, 2025Albemarle Corporation announced that they will report Q3, 2025 results After-Market on Nov 05, 2025Upcoming Dividend • Sep 05Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 12 September 2025. Payment date: 01 October 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.5%). Lower than average of industry peers (4.3%).お知らせ • Aug 12Albemarle Announces Executive Changes, Effective August 11, 2025Albemarle Corporation announced changes to its organizational structure to further align the company for agility and efficiency. These enhancements are designed to accelerate the company's market-led enterprise strategy and focus on operational excellence. Effective as of August 11, 2025: Mark Mummert will lead an integrated function of resources, manufacturing, capital and supply chain as chief operations officer continuing to report to Kent Masters, Albemarle's chairman and CEO. In this role, he will ensure optimization of Albemarle's world-class resources, including joint venture management, as well as global manufacturing. In addition, he will oversee capital projects and supply chain in a fully integrated operating model. With this change, Netha Johnson is leaving the company. Autumn Gagarinas will become Albemarle's chief people and workplace transformation officer, also reporting to Masters, to focus on talent and culture, as well as business process and technology optimization. Autumn has been serving as Albemarle's vice president of human resources for over two years and has over two decades of human resources experience. Melissa Anderson will continue to report to Masters and will lead Albemarle's enterprise strategy and growth, as well as research and technology as chief business transformation officer.Reported Earnings • Jul 31Second quarter 2025 earnings released: EPS: US$0.20 (vs US$1.96 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.20 (up from US$1.96 loss in 2Q 2024). Revenue: US$1.33b (down 7.0% from 2Q 2024). Net income: US$22.9m (up US$252.8m from 2Q 2024). Profit margin: 1.7% (up from net loss in 2Q 2024). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.お知らせ • Jul 31Albemarle Corporation Announces Executive Changeslbemarle Corporation announced that Ander Krupa has been promoted to executive vice president, general counsel, corporate secretary, and chief compliance officer. Krupa joined Albemarle in May 2017 as vice president, deputy general counsel, and assistant corporate secretary. He has served in leadership roles supporting Albemarle's global business units, commercial activities, and mergers and acquisitions. Krupa has more than 15 years of practice in the manufacturing industry and deep experience across Albemarle's businesses. Prior to Albemarle, Krupa served as assistant general counsel, governance, and securities for BWX Technologies Inc. and The Babcock & Wilcox Company. He was also an attorney with the international law firm of Greenberg Traurig LLP in the firm's corporate and securities practice group. Krupa received a bachelor's degree from the University of Georgia and earned his J.D. from Georgia State University College of Law. He is based in the company's Charlotte, N.C., headquarters and will report to Kent Masters as part of Albemarle's executive leadership team. Krupa assumes the role following the passing in April of Albemarle's former general counsel, corporate secretary, and chief compliance officer, Stacy Grant, at which time he was named as interim general counsel.Declared Dividend • Jul 28First quarter dividend of US$0.41 announcedDividend of US$0.41 is the same as last year. Ex-date: 12th September 2025 Payment date: 1st October 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.お知らせ • Jul 23Albemarle Corporation Declares Quarterly Common Stock Dividend, Payable on October 1, 2025The Board of Directors of Albemarle Corp. announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable October 1, 2025, to shareholders of record at the close of business as of September 12, 2025.お知らせ • Jun 19Albemarle Corporation to Report Q2, 2025 Results on Jul 30, 2025Albemarle Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025Upcoming Dividend • Jun 06Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 13 June 2025. Payment date: 01 July 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (4.1%).Buy Or Sell Opportunity • May 30Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to US$55.42. The fair value is estimated to be US$70.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 1.7% in a year. Earnings are forecast to grow by 100% in the next year.Declared Dividend • May 12First quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 13th June 2025 Payment date: 1st July 2025 Dividend yield will be 2.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.お知らせ • May 07Albemarle Announces Quarterly Common Stock Dividend, Payable on July 1, 2025The Board of Directors of Albemarle Corp. announced that it declared a quarterly common stock dividend of $0.405 per share. This marks Albemarle's 126th consecutive quarterly cash dividend. The dividend, which has an annualized rate of $1.62, is payable July 1, 2025, to shareholders of record at the close of business as of June 13, 2025.Reported Earnings • May 01First quarter 2025 earnings released: US$0.003 loss per share (vs US$0.078 loss in 1Q 2024)First quarter 2025 results: US$0.003 loss per share (improved from US$0.078 loss in 1Q 2024). Revenue: US$1.08b (down 21% from 1Q 2024). Net loss: US$340.0k (loss narrowed 96% from 1Q 2024). Profit margin: 0% (up from net loss in 1Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change).お知らせ • Apr 03Albemarle Corporation to Report Q1, 2025 Results on Apr 30, 2025Albemarle Corporation announced that they will report Q1, 2025 results After-Market on Apr 30, 2025お知らせ • Mar 29Albemarle Corporation, Annual General Meeting, May 06, 2025Albemarle Corporation, Annual General Meeting, May 06, 2025. Location: 4250 congress street, nc 28209, charlotte, United Statesお知らせ • Mar 24Albemarle Corporation(NYSE:ALB) dropped from FTSE All-World Index (USD)Albemarle Corporation(NYSE:ALB) dropped from FTSE All-World Index (USD)Declared Dividend • Mar 02Fourth quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 14th March 2025 Payment date: 1st April 2025 Dividend yield will be 2.1%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.お知らせ • Feb 28Albemarle Corporation Announces Quarterly Common Stock Dividend, Payable on April 1, 2025The Board of Directors of Albemarle Corporation announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable April 1, 2025, to shareholders of record at the close of business as of March 14, 2025.Reported Earnings • Feb 13Full year 2024 earnings released: US$11.20 loss per share (vs US$13.41 profit in FY 2023)Full year 2024 results: US$11.20 loss per share (down from US$13.41 profit in FY 2023). Revenue: US$5.38b (down 44% from FY 2023). Net loss: US$1.32b (down 184% from profit in FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.New Risk • Feb 10New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).お知らせ • Jan 10Albemarle Corporation to Report Q4, 2024 Results on Feb 12, 2025Albemarle Corporation announced that they will report Q4, 2024 results After-Market on Feb 12, 2025Recent Insider Transactions • Dec 08Chairman recently sold US$255k worth of stockOn the 5th of December, Jerry Masters sold around 3k shares on-market at roughly US$101 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jerry's only on-market trade for the last 12 months.Upcoming Dividend • Dec 06Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 13 December 2024. Payment date: 02 January 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (3.8%).Reported Earnings • Nov 07Third quarter 2024 earnings released: US$9.45 loss per share (vs US$2.58 profit in 3Q 2023)Third quarter 2024 results: US$9.45 loss per share (down from US$2.58 profit in 3Q 2023). Revenue: US$1.35b (down 41% from 3Q 2023). Net loss: US$1.11b (down 467% from profit in 3Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.Declared Dividend • Nov 04Second quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 13th December 2024 Payment date: 2nd January 2025 Dividend yield will be 1.6%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.お知らせ • Oct 07Albemarle Corporation Announces Executive ChangesAlbemarle Corporation announced the company’s new operating structure to adapt to dynamic market conditions. As part of this change, effective Nov. 1, 2024: Specialties Business President Netha Johnson will become chief operations officer and continues to report to Chairman and CEO Kent Masters. In this role, he will lead global manufacturing, research and technology, capital projects and process chemistry execution. Johnson joined Albemarle in 2018 and has more than 25 years of experience in global manufacturing, leadership and general management. Energy Storage Business President Eric Norris will become chief commercial officer and continues to report to Masters. In this role, he will oversee enterprise product management, sales and commercial excellence. Norris joined Albemarle in 2018 and has more than 25 years of experience in strategy, corporate development and general management. In addition, the following leaders will report to Masters: Melissa Anderson will become chief transformation officer, effective Nov. 1, which reflects her current oversight of people, strategy and transformation; Stacy Grant will become general counsel, corporate secretary and chief compliance officer, effective immediately, and succeeds Kristin Coleman, who is leaving the company. Grant joined Albemarle in 2023 and previously served as vice president & deputy general counsel, global corporate affairs; Mark Mummert will become chief capital, resources and integrated supply chain officer, effective Nov. 1, which includes expanded responsibility for resources, joint venture management, customer service and operational excellence. On October 7, 2024, in connection with the implementation of the new operating structure described in Item 7.01 below, Kristin Coleman will cease serving as Executive Vice President, General Counsel and Corporate Secretary of the Company and her last day of employment will be November 4, 2024. In addition, in connection with the implementation of such new operating structure, John C. Barichivich III will cease serving as Vice President, Corporate Controller and Chief Accounting Officer of the company effective upon the appointment of his successor, and his last day of employment will be December 31, 2024.お知らせ • Oct 01Albemarle Corporation to Report Q3, 2024 Results on Nov 06, 2024Albemarle Corporation announced that they will report Q3, 2024 results After-Market on Nov 06, 2024Upcoming Dividend • Sep 06Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 13 September 2024. Payment date: 01 October 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.5%). Lower than average of industry peers (3.3%).New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).お知らせ • Aug 13Albemarle Reportedly May Look to Offload 49% Stake in Greenbushes Lithium Mine to IGOSpeculation is mounting that US-based Albemarle Corporation (NYSE:ALB) may be considering selling down its 49% stake in the Greenbushes lithium mine to its Australian-listed partner IGO Limited (ASX:IGO), after the world's largest lithium producer this month slashed jobs and shut part of a processing facility in Western Australia. Greenbushes in WA is a global standout, and there is scepticism about the market chatter, although IGO wants to buy more of the asset should it be available, say sources. IGO did not comment. One reason a sale may be on the table is that Greenbushes does not qualify for the Inflation Reduction Act benefits in the US because of its partial Chinese ownership of 25.1%. To quality, Chinese ownership would need to be 24.9% or less, although the US government may show some leniency. IGO and China's Tianqi both own 51% in a joint venture arrangement. US-based lithium specialist Albemarle owns the remainder. The Australian reported last month that Albemarle, Tianqi and IGO would be taking the brakes off the giant Greenbushes mine despite low lithium prices, with the mine set to lift production over the next year as IGO intensifies its hunt for growth opportunities.Reported Earnings • Aug 01Second quarter 2024 earnings released: US$1.96 loss per share (vs US$5.54 profit in 2Q 2023)Second quarter 2024 results: US$1.96 loss per share (down from US$5.54 profit in 2Q 2023). Revenue: US$1.43b (down 40% from 2Q 2023). Net loss: US$229.9m (down 135% from profit in 2Q 2023). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Declared Dividend • Jul 19First quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 13th September 2024 Payment date: 1st October 2024 Dividend yield will be 1.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 191% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jul 02Albemarle Corporation to Report Q2, 2024 Results on Jul 31, 2024Albemarle Corporation announced that they will report Q2, 2024 results After-Market on Jul 31, 2024Upcoming Dividend • Jun 07Upcoming dividend of US$0.40 per shareEligible shareholders must have bought the stock before 14 June 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 58% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (3.1%).Declared Dividend • May 12First quarter dividend of US$0.40 announcedDividend of US$0.40 is the same as last year. Ex-date: 14th June 2024 Payment date: 1st July 2024 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 186% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 03Albemarle Corporation Reaffirms Earnings Guidance for the Year 2024Albemarle Corporation reaffirmed earnings guidance for the year 2024. For the period, the company expects net sales of $5.5 billion to $6.2 billion.Reported Earnings • May 02First quarter 2024 earnings released: US$0.078 loss per share (vs US$10.57 profit in 1Q 2023)First quarter 2024 results: US$0.078 loss per share (down from US$10.57 profit in 1Q 2023). Revenue: US$1.36b (down 47% from 1Q 2023). Net loss: US$9.14m (down 101% from profit in 1Q 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Apr 07Albemarle Corporation to Report Q1, 2024 Results on May 01, 2024Albemarle Corporation announced that they will report Q1, 2024 results After-Market on May 01, 2024お知らせ • Mar 13Albemarle Corporation, Annual General Meeting, May 07, 2024Albemarle Corporation, Annual General Meeting, May 07, 2024, at 07:00 Eastern Standard Time. Location: Albemarle Corporation, 4250 Congress Street, Charlotte, North Carolina 28209, Charlotte North Carolina United States Agenda: To consider and Elect the ten nominees; to approve, on a non-binding advisory basis, the compensation of named executive officers; to approve an amendment to Albemarle's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock; to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.Upcoming Dividend • Mar 07Upcoming dividend of US$0.40 per shareEligible shareholders must have bought the stock before 14 March 2024. Payment date: 01 April 2024. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of British dividend payers (6.3%). Lower than average of industry peers (3.1%).Valuation Update With 7 Day Price Move • Mar 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to US$138, the stock trades at a forward P/E ratio of 21x. Average trailing P/E is 17x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 2.5% over the past three years.Declared Dividend • Feb 25Fourth quarter dividend of US$0.40 announcedDividend of US$0.40 is the same as last year. Ex-date: 14th March 2024 Payment date: 1st April 2024 Dividend yield will be 1.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 16Full year 2023 earnings released: EPS: US$13.41 (vs US$22.97 in FY 2022)Full year 2023 results: EPS: US$13.41 (down from US$22.97 in FY 2022). Revenue: US$9.62b (up 31% from FY 2022). Net income: US$1.57b (down 42% from FY 2022). Profit margin: 16% (down from 37% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Jan 19Albemarle Reportedly Selling Out of LiontownAlbemarle Corporation (NYSE:ALB) has appointed brokers to sell its stake in Liontown Resources Limited (ASX:LTR), three months after Hancock Prospecting effectively blocked its $6.6 billion takeover bid. JP Morgan was looking to sell Albemarle's 4% stake after the market closed, at prices ranging from $1.26 per share to $1.32 per share. With Albemarle holding 96 million Liontown shares, the deal will be worth about $125 million. The planned sale will be at a loss for Albemarle, which was understood to have acquired its stake at an average entry price of $2.35 per share. Albemarle attempted four times to acquire Liontown, which is developing the Kathleen Valley lithium mine in the Goldfields. The mine would have provided a new supply for Albemarle's downstream processing operations, including its lithium refinery at Kemerton in the South West. It lodged indicative proposals at $2.20 per share in October 2022, $2.35 in March 2023 and $2.50 later that month. It appeared to have succeeded in September when the Liontown board backed its fourth proposal - a takeover bid priced at $3 per share. However Australia's richest person, Gina Rinehart, ended the party after her private company Hancock Prospecting acquired a 19.9% blocking stake. Albemarle scrapped its takeover bid in mid-October, triggering a collapse in Liontown's share price and forcing the company to complete an equity and debt raising to ensure it could complete construction at Kathleen Valley. Hancock has retained its 19.9% stake but has been silent on its intentions.お知らせ • Jan 12Albemarle Corporation to Report Q4, 2023 Results on Feb 14, 2024Albemarle Corporation announced that they will report Q4, 2023 results After-Market on Feb 14, 2024Upcoming Dividend • Dec 07Upcoming dividend of US$0.40 per share at 1.4% yieldEligible shareholders must have bought the stock before 14 December 2023. Payment date: 02 January 2024. Payout ratio is a comfortable 5.6% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (3.2%).New Risk • Nov 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).お知らせ • Nov 18Albemarle Corporation Announces the Promotion of Cynthia Lima as Senior Vice President, Chief External Affairs and Communications OfficerAlbemarle Corporation announced that Cynthia Lima has been promoted to senior vice president, chief external affairs and communications officer. Lima joined Albemarle early in 2023 as chief communications officer and has expanded her remit to include the global external affairs function. She brings extensive government affairs and communications experience spanning both public and private sectors. Prior to joining Albemarle, Lima founded a communications and public affairs consultancy and held senior positions at domestic and global public relations agencies. Previously, Lima served in the U.S. Department of State and U.S. Department of Veterans Affairs where she was a senate-confirmed presidential appointee. Lima is based in the company's Charlotte, N.C., headquarters and will report to Masters as part of Albemarle's Executive Leadership Team.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$2.58 (vs US$7.66 in 3Q 2022)Third quarter 2023 results: EPS: US$2.58 (down from US$7.66 in 3Q 2022). Revenue: US$2.31b (up 11% from 3Q 2022). Net income: US$302.5m (down 66% from 3Q 2022). Profit margin: 13% (down from 43% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 02Albemarle Corporation Revises Net Sales Guidance for the Full Year 2023Albemarle Corporation revised net sales guidance for the full year 2023. For the year, the company now expects net sales to be in the range of $9.5 billion to $9.8 billion against previous guidance of $10.4 billion to $11.5 billion.お知らせ • Oct 28Albemarle Corporation Announces CFO Changes, Effective on November 6, 2023Albemarle Corporation announced that Neal Sheorey will join Albemarle as its chief financial officer, effective Nov. 6, 2023. Scott Tozier, Albemarle's current chief financial officer, will transition from his current role and become a strategic advisor to the CEO. Sheorey joins Albemarle from Dow, a global materials science company, where he served for more than 20 years in progressive finance, business, and corporate leadership roles. Most recently, he was vice president of Dow's Coatings & Performance Monomers business unit, a global portfolio with more than $4 billion in sales, where he was responsible for the group's strategy, profitability, and growth initiatives. Prior to his current role, Sheorey served as Dow's vice president of investor relations, senior director of corporate development and global finance director for the Chemicals business group. Sheorey holds a master's degree in business administration with a concentration in finance and corporate strategy from the University of Michigan, and a bachelor's degree in chemical engineering from Northwestern University. Tozier joined Albemarle in 2011 as senior vice president and chief financial officer.お知らせ • Oct 27Albemarle Corporation Announces Executive Changes, Effective on November 6, 2023Albemarle Corporation announced that Neal Sheorey will join Albemarle as its executive vice president, effective Nov. 6, 2023. Scott Tozier, Albemarle's current executive vice president will transition from his current role and become a strategic advisor to the CEO. Sheorey joins Albemarle from Dow, a global materials science company, where he served for more than 20 years in progressive finance, business, and corporate leadership roles. Most recently, he was vice president of Dow's Coatings & Performance Monomers business unit, a global portfolio with more than $4 billion in sales, where he was responsible for the group's strategy, profitability, and growth initiatives. Prior to his current role, Sheorey served as Dow's vice president of investor relations, senior director of corporate development and global finance director for the Chemicals business group. Sheorey holds a master's degree in business administration with a concentration in finance and corporate strategy from the University of Michigan, and a bachelor's degree in chemical engineering from Northwestern University. Tozier joined Albemarle in 2011 as senior vice president and chief financial officer.Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$140, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 53% over the past three years.お知らせ • Oct 20Albemarle Corporation (NYSE:ALB) completed the acquisition of additional 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources Limited (ASX:MIN)Albemarle Corporation (NYSE:ALB) entered into binding agreement to acquire additional 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources Limited (ASX:MIN) on February 23, 2023. As of July 19, 2023, Albemarle Corporation amend the terms of the transaction and agreed to acquire remaining 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources for approximately AUD 590 million ($400 million). Albemarle will supply MinRes’ 15% share of spodumene concentrate for use by Kemerton from the Greenbushes mine. MinRes will pay the benchmark price for its share of Greenbushes spodumene concentrate. In similar transaction Albemarle Corporation entered into binding agreement ownership of the Wodgina mine to change from 60% and 40% to 50% and50%. Albemarle is expected to pay MinRes a completion adjustment currently estimated to be AUD 150 million. As of July 19, 2023, upon closing, Albemarle expects to pay Mineral Resources $380 (AUD 557.5 million) - $400 million (AUD 586.9 million) which includes net consideration for the remaining 15% ownership of Kemerton as well as EED settlement adjustments. Actual settlement adjustments will depend on the date of close. The acquisition is subject to regulatory approvals. The parties anticipate closing the amended arrangements later this year. As of August 2, 2023, the transaction is expected to close in the second half of 2023. Herbert Smith Freehills LLP acted as legal advisor to Kemerton Lithium Hydroxide Plant. Albemarle Corporation (NYSE:ALB) completed the acquisition of additional 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources Limited (ASX:MIN) on October 18, 2023.お知らせ • Oct 16Albemarle Withdraws Non-Binding Offer to Acquire Liontown ResourcesOn October 15, 2023, Albemarle Corporation (NYSE:ALB) announced that it will not pursue a binding agreement to purchase Liontown Resources Limited (ASX:LTR) and has formally withdrawn its non-binding offer to Liontown's board of directors. The decision comes as Albemarle nears the end of its exclusive due diligence process. "Our engagement with the Liontown team has been meaningful and productive. We appreciate the level of cooperation we have received, and we thank the entire team for their efforts," said Kent Masters, Chief Executive Officer of Albemarle. "That said, moving forward with the acquisition, at this time, is not in Albemarle's best interests." The company noted growing complexities associated with the proposed transaction as a factor in its decision. The announcement is consistent with Albemarle's disciplined approach to capital allocation and the company will continue to execute its long-term growth strategy. Planned expansions to deliver volumetric growth continue to progress across the company's global portfolio. Albemarle's capital allocation priorities remain investing in high-return organic and inorganic growth, maintaining its financial flexibility and investment grade credit rating, and funding its dividends. Albemarle is one of Australia's biggest lithium investors, with mining assets at Wodgina and Greenbushes, and with the Kemerton lithium hydroxide plant, which is currently undergoing a significant expansion.お知らせ • Oct 06Albemarle Corporation to Report Q3, 2023 Results on Nov 01, 2023Albemarle Corporation announced that they will report Q3, 2023 results After-Market on Nov 01, 2023Upcoming Dividend • Sep 07Upcoming dividend of US$0.40 per share at 0.8% yieldEligible shareholders must have bought the stock before 14 September 2023. Payment date: 02 October 2023. Payout ratio is a comfortable 4.8% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of British dividend payers (6.3%). Lower than average of industry peers (2.8%).お知らせ • Sep 06Albemarle Makes Another Sweetened Bid for LiontownRecently rejected suitor, US specialty chemicals firm Albemarle Corporation (NYSE:ALB) has tabled a sweetened bid to acquire Australian lithium start-up Liontown Resources Limited (ASX:LTR) in a deal valuing the target company at about AUD 6.6 billion (USD 4.26 billion/EUR 3.95 billion). Albemarle’s new, conditional and non-binding indicative proposal provides for each Liontown share to be exchanged for AUD 3.00 apiece. It is Albemarle’s best and final proposal, in the absence of a superior proposal, according to a statement from September 4, 2023. The Australian firm said that its board has determined to grant Albemarle an opportunity to conduct a limited period of exclusive due diligence, subject to customary fiduciary exceptions, to enable it to put forward a binding proposal. Liontown at the end of March turned down an improved AUD-5.5-billion takeover bid from Albemarle considering the offer substantially under-priced. The previous bid implied a consideration of AUD 2.50 per Liontown share.お知らせ • Aug 04Albemarle Corporation Revises Earnings Guidance for the Fiscal Year 2023Albemarle Corporation revised earnings guidance for the fiscal year 2023. For the fiscal, the company expects net sales of $10.4 billion - $11.5 billion from previous guidance of $9.8 - $11.5 billion.New Risk • Aug 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. High level of non-cash earnings (29% accrual ratio).Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: US$5.54 (vs US$3.47 in 2Q 2022)Second quarter 2023 results: EPS: US$5.54 (up from US$3.47 in 2Q 2022). Revenue: US$2.37b (up 60% from 2Q 2022). Net income: US$650.0m (up 60% from 2Q 2022). Profit margin: 27% (in line with 2Q 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 12Albemarle Corporation to Report Q2, 2023 Results on Aug 02, 2023Albemarle Corporation announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2023お知らせ • Jun 25Albemarle Corporation(NYSE:ALB) dropped from Russell 1000 Growth IndexAlbemarle Corporation(NYSE:ALB) dropped from Russell 1000 Growth IndexUpcoming Dividend • Jun 08Upcoming dividend of US$0.40 per share at 0.7% yieldEligible shareholders must have bought the stock before 15 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 5.1% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.5%).Recent Insider Transactions • May 16President of Albemarle Energy Storage recently bought US$246k worth of stockOn the 10th of May, Eric Norris bought around 1k shares on-market at roughly US$195 per share. This transaction amounted to 5.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$994k. Despite this recent purchase, insiders have collectively sold US$3.1m more in shares than they bought in the last 12 months.Recent Insider Transactions • May 09Chairman & CEO recently bought US$994k worth of stockOn the 5th of May, Jerry Masters bought around 5k shares on-market at roughly US$182 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jerry's only on-market trade for the last 12 months.お知らせ • May 05Albemarle Corporation Revises Earnings Guidance for the Full Year 2023Albemarle Corporation revised earnings guidance for the full year 2023. For the year, the company’s net sales are expected to increase 35% to 55% over prior year, primarily driven by a continued global shift to electric vehicles. Net sales are now expected to be in the range of $9.8 billion to $11.5 billion compared to previous guidance of $11.3 billion to $12.9 billion.Reported Earnings • May 04First quarter 2023 earnings released: EPS: US$10.57 (vs US$2.16 in 1Q 2022)First quarter 2023 results: EPS: US$10.57 (up from US$2.16 in 1Q 2022). Revenue: US$2.58b (up 129% from 1Q 2022). Net income: US$1.24b (up 389% from 1Q 2022). Profit margin: 48% (up from 23% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$174, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 208% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$328 per share.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$212, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 12x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 230% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$356 per share.Upcoming Dividend • Mar 09Upcoming dividend of US$0.40 per share at 0.6% yieldEligible shareholders must have bought the stock before 16 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 6.9% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (3.0%).Buying Opportunity • Feb 18Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 7.7%. The fair value is estimated to be US$336, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 51%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 1.1% per annum over the same time period.Reported Earnings • Feb 17Full year 2022 earnings released: EPS: US$22.97 (vs US$1.07 in FY 2021)Full year 2022 results: EPS: US$22.97 (up from US$1.07 in FY 2021). Revenue: US$7.32b (up 120% from FY 2021). Net income: US$2.69b (up US$2.57b from FY 2021). Profit margin: 37% (up from 3.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$278, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 257% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$318 per share.お知らせ • Jan 24Albemarle Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 and Full Year of 2023Albemarle Corporation provides revenue guidance for the fourth quarter and full year ended December 31, 2022 and full year of 2023. For the quarter of 2022, company expects Net sales of between $2,590 million and $2,650 million, up 190% to 196%, Net income in the range of $1,107 million to $1,157 million and Diluted EPS of between $9.30 and $9.80. For the year of 2022, company expects Net sales of between $7,290 million - $7,350 million, Net income (loss) attributable to Albemarle Corporation $2,662 million - $2,712 million and Diluted earnings (loss) per share $22.50 - $23.00. For the year of 2023, company expects Net sales of $11.3 billion - $12.9 billion.お知らせ • Jan 18Albemarle Corporation to Report Q4, 2022 Results on Feb 15, 2023Albemarle Corporation announced that they will report Q4, 2022 results After-Market on Feb 15, 2023Buying Opportunity • Jan 10Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be US$277, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 7.0%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.株主還元0HC7GB ChemicalsGB 市場7D-11.8%0.3%0.5%1Y194.3%9.7%18.0%株主還元を見る業界別リターン: 0HC7過去 1 年間で9.7 % の収益を上げたUK Chemicals業界を上回りました。リターン対市場: 0HC7過去 1 年間で18 % の収益を上げたUK市場を上回りました。価格変動Is 0HC7's price volatile compared to industry and market?0HC7 volatility0HC7 Average Weekly Movement8.4%Chemicals Industry Average Movement8.0%Market Average Movement5.7%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.1%安定した株価: 0HC7の株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 0HC7の weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてUKの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト18877,800Jerry Masterswww.albemarle.comアルベマール・コーポレーションは世界中でエネルギー貯蔵ソリューションを提供している。3つのセグメントで事業を展開している：エネルギー貯蔵、スペシャリティーズ、ケッチェンである。エネルギー貯蔵部門は、家電製品や電気自動車に使用されるリチウム電池、送電網やソーラーパネル、高性能グリース、家電製品や電子機器に使用される特殊ガラスに使用される炭酸リチウム、水酸化リチウム、塩化リチウムなどのリチウム化合物を提供している。スペシャリティーズ部門は、エネルギー、モビリティ、コネクティビティ、火災安全化合物を含む健康など、様々な産業向けに臭素と高度に特殊化されたリチウムソリューションを提供する。臭素ベースのスペシャリティーケミカルズ製品としては、元素状臭素、臭化アルキル、無機臭化物、臭素化粉末活性炭、各種臭素ファインケミカルなどがある；ブチルリチウムや水素化アルミニウムリチウムなどのリチウム特殊化学品、化学・製薬業界向けのセシウム製品、エアバッグ用イニシエーターなどの火工品用途向けのジルコニウム、バリウム、チタン製品。また、ステロイド化学やビタミン、様々なライフサイエンス分野での有機合成プロセスや、製薬産業での中間体、反応性リチウム製品の取り扱いや使用を含む技術サービス、リチウム含有副産物のリサイクルサービスも提供している。ケッチェン部門は、異性化・アルキル化触媒を含む水素化分解触媒、流動接触分解触媒と添加剤、有機金属と硬化剤からなる性能触媒ソリューションなどのクリーン燃料技術を提供している。グリッド・ストレージ、自動車、航空宇宙、従来型エネルギー、エレクトロニクス、建設、農業、食品、製薬、医療機器業界にサービスを提供している。アルベマール・コーポレーションは1887年に設立され、ノースカロライナ州シャーロットに本社を置いている。もっと見るAlbemarle Corporation 基礎のまとめAlbemarle の収益と売上を時価総額と比較するとどうか。0HC7 基礎統計学時価総額US$20.07b収益（TTM）-US$399.63m売上高(TTM)US$5.49b3.7xP/Sレシオ-50.2xPER（株価収益率0HC7 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0HC7 損益計算書（TTM）収益US$5.49b売上原価US$4.48b売上総利益US$1.02bその他の費用US$1.42b収益-US$399.63m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-3.39グロス・マージン18.53%純利益率-7.27%有利子負債／自己資本比率17.6%0HC7 の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.0%現在の配当利回り-48%配当性向0HC7 配当は確実ですか？0HC7 配当履歴とベンチマークを見る0HC7 、いつまでに購入すれば配当金を受け取れますか？Albemarle 配当日配当落ち日Jun 12 2026配当支払日Jul 01 2026配当落ちまでの日数21 days配当支払日までの日数40 days0HC7 配当は確実ですか？0HC7 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 19:33終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Albemarle Corporation 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。37 アナリスト機関William SeleskyArgus Research CompanyBenjamin KalloBairdAndres Castanos-MollorBerenberg34 その他のアナリストを表示
Recent Insider Transactions • 20hChairman recently sold US$3.0m worth of stockOn the 15th of May, Jerry Masters sold around 16k shares on-market at roughly US$184 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jerry has been a net seller over the last 12 months, reducing personal holdings by US$5.0m.
Reported Earnings • May 12First quarter 2026 earnings released: EPS: US$2.35 (vs US$0.003 loss in 1Q 2025)First quarter 2026 results: EPS: US$2.35 (up from US$0.003 loss in 1Q 2025). Revenue: US$1.43b (up 33% from 1Q 2025). Net income: US$277.4m (up US$277.7m from 1Q 2025). Profit margin: 19% (up from 0% in 1Q 2025). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.
お知らせ • May 07Albemarle Corporation announces Quarterly dividend, payable on July 01, 2026Albemarle Corporation announced Quarterly dividend of USD 0.4050 per share payable on July 01, 2026, ex-date on June 12, 2026 and record date on June 12, 2026.
お知らせ • Apr 07Albemarle Corporation to Report Q1, 2026 Results on May 06, 2026Albemarle Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026
お知らせ • Mar 25Albemarle Corporation Announces Director James O’Brien Will Not Stand for Re-Election, Effective May 5, 2026Albemarle Corporation announced James O’Brien, director will not stand for reelection. James O’Brien's directorship will end effective at the Annual Meeting to be held on May 5, 2026 pursuant to attained the age of 72 in 2026, and, accordingly, is not nominated for re-election at this annual meeting.
お知らせ • Mar 12Albemarle Corporation, Annual General Meeting, May 05, 2026Albemarle Corporation, Annual General Meeting, May 05, 2026. Location: 4250 congress street north carolina 28209, charlotte, United States
Recent Insider Transactions • 20hChairman recently sold US$3.0m worth of stockOn the 15th of May, Jerry Masters sold around 16k shares on-market at roughly US$184 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Jerry has been a net seller over the last 12 months, reducing personal holdings by US$5.0m.
Reported Earnings • May 12First quarter 2026 earnings released: EPS: US$2.35 (vs US$0.003 loss in 1Q 2025)First quarter 2026 results: EPS: US$2.35 (up from US$0.003 loss in 1Q 2025). Revenue: US$1.43b (up 33% from 1Q 2025). Net income: US$277.4m (up US$277.7m from 1Q 2025). Profit margin: 19% (up from 0% in 1Q 2025). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 104 percentage points per year, which is a significant difference in performance.
お知らせ • May 07Albemarle Corporation announces Quarterly dividend, payable on July 01, 2026Albemarle Corporation announced Quarterly dividend of USD 0.4050 per share payable on July 01, 2026, ex-date on June 12, 2026 and record date on June 12, 2026.
お知らせ • Apr 07Albemarle Corporation to Report Q1, 2026 Results on May 06, 2026Albemarle Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 06, 2026
お知らせ • Mar 25Albemarle Corporation Announces Director James O’Brien Will Not Stand for Re-Election, Effective May 5, 2026Albemarle Corporation announced James O’Brien, director will not stand for reelection. James O’Brien's directorship will end effective at the Annual Meeting to be held on May 5, 2026 pursuant to attained the age of 72 in 2026, and, accordingly, is not nominated for re-election at this annual meeting.
お知らせ • Mar 12Albemarle Corporation, Annual General Meeting, May 05, 2026Albemarle Corporation, Annual General Meeting, May 05, 2026. Location: 4250 congress street north carolina 28209, charlotte, United States
お知らせ • Mar 03+ 1 more updateKPS Capital Partners, LP completed the acquisition of 51% stake in Ketjen Corporation from Albemarle Corporation (NYSE:ALB).KPS Capital Partners, LP entered into a Stock Purchase Agreement to acquire Ketjen Corporation from Albemarle Corporation (NYSE:ALB) for $800 million on October 25, 2025. Under the terms of the Stock Purchase Agreement, Albemarle Corporation will sell 51% of the common stock of Ketjen (Purchased Shares) to KPS Capital Partners and contribute remaining 49% of common stock of Ketjen to Holdco, that was organized by and is affiliated with KPS Capital Partners LP. At the closing of the sale, contribution and other transactions contemplated by the Stock Purchase Agreement (collectively, the “Transaction”), Albemarle will receive an estimated $536 million in cash and will own common units of Holdco (the “Rollover Equity”). Under the Stock Purchase Agreement, the purchase price for the Purchased Shares is $800.0 million, less the value ascribed to the Contributed Shares pursuant to the terms and conditions of the Stock Purchase Agreement, and is further subject to adjustment for closing cash, indebtedness, net working capital and transaction expenses. Albemarle and KPS, through affiliates, will own approximately 49% and 51% of Ketjen at close, respectively, with KPS having a majority of the Board of Directors and operational control of Ketjen. The debt financing has been provided by Barclays, Jefferies, BNP Paribas and Santander. The termination fee of $32.5 million has to be paid by KPS Capital Partners, LP to Albemarle Corporation, if the closing has not occurred by April 30, 2026. The transactions is expected to be completed in the first half of 2026, with both subject to customary closing conditions and regulatory approvals, including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), as well as approvals from competition and foreign investment authorities from certain non-U.S. jurisdictions and certain other governmental authorities. Goldman Sachs & Co. LLC acted as financial advisor and K&L Gates LLP acted as legal advisor for Albemarle Corporation. Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor and Raymond James Financial, Inc. acted as financial advisor for KPS Capital Partners, LP. Roel Fluit, Michel van Agt, Guido Koop, and Vincent van der Lans of Loyens & Loeff acted as legal advisor to KPS Capital Partners. KPS Capital Partners, LP completed the acquisition of 51% stake in Ketjen Corporation from Albemarle Corporation (NYSE:ALB) on March 2, 2026. Albemarle will retain reamining 49% stake in Ketjen.
お知らせ • Feb 27Albemarle Corp. Announces Quarterly Common Stock Dividend, Payable on April 1, 2026The Board of Directors of Albemarle Corporation announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable April 1, 2026, to shareholders of record at the close of business as of March 13, 2026.
お知らせ • Feb 12+ 2 more updatesAlbemarle Corporation Provides Earnings Guidance for 2026Albemarle Corporation provided earnings guidance for 2026. For the period the company expects the Net sales of $5.7 billion to $6.0 billion. Sales volumes are expected to be approximately flat following inventory drawdowns that occurred in 2025.
お知らせ • Jan 14Albemarle Corporation to Report Q4, 2025 Results on Feb 11, 2026Albemarle Corporation announced that they will report Q4, 2025 results After-Market on Feb 11, 2026
お知らせ • Dec 13Albemarle Corporation Announces Resignation of Dean L. Seavers as Director, Effective December 12, 2025Albemarle Corporation announced that Dean L. Seavers tendered his resignation from the Board of Directors and all committees on which he serves, effective December 12, 2025.
Upcoming Dividend • Dec 05Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 12 December 2025. Payment date: 02 January 2026. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (4.0%).
Reported Earnings • Nov 06Third quarter 2025 earnings released: US$1.72 loss per share (vs US$9.45 loss in 3Q 2024)Third quarter 2025 results: US$1.72 loss per share (improved from US$9.45 loss in 3Q 2024). Revenue: US$1.31b (down 3.5% from 3Q 2024). Net loss: US$202.4m (loss narrowed 82% from 3Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 06+ 1 more updateAlbemarle Corporation Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2025Albemarle Corporation announced Goodwill impairment charges for the third quarter ended September 30, 2025. For the period, the company reported Goodwill impairment charges of $181,070,000.
Declared Dividend • Nov 03Second quarter dividend of US$0.41 announcedDividend of US$0.41 is the same as last year. Ex-date: 12th December 2025 Payment date: 2nd January 2026 Dividend yield will be 1.6%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
お知らせ • Oct 28Albemarle Corp. Announces Quarterly Common Stock Dividend, Payable on January 2, 2026The Board of Directors of Albemarle Corp. announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable January 2, 2026, to shareholders of record at the close of business as of December 12, 2025.
お知らせ • Sep 26Albemarle Corporation to Report Q3, 2025 Results on Nov 05, 2025Albemarle Corporation announced that they will report Q3, 2025 results After-Market on Nov 05, 2025
Upcoming Dividend • Sep 05Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 12 September 2025. Payment date: 01 October 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.5%). Lower than average of industry peers (4.3%).
お知らせ • Aug 12Albemarle Announces Executive Changes, Effective August 11, 2025Albemarle Corporation announced changes to its organizational structure to further align the company for agility and efficiency. These enhancements are designed to accelerate the company's market-led enterprise strategy and focus on operational excellence. Effective as of August 11, 2025: Mark Mummert will lead an integrated function of resources, manufacturing, capital and supply chain as chief operations officer continuing to report to Kent Masters, Albemarle's chairman and CEO. In this role, he will ensure optimization of Albemarle's world-class resources, including joint venture management, as well as global manufacturing. In addition, he will oversee capital projects and supply chain in a fully integrated operating model. With this change, Netha Johnson is leaving the company. Autumn Gagarinas will become Albemarle's chief people and workplace transformation officer, also reporting to Masters, to focus on talent and culture, as well as business process and technology optimization. Autumn has been serving as Albemarle's vice president of human resources for over two years and has over two decades of human resources experience. Melissa Anderson will continue to report to Masters and will lead Albemarle's enterprise strategy and growth, as well as research and technology as chief business transformation officer.
Reported Earnings • Jul 31Second quarter 2025 earnings released: EPS: US$0.20 (vs US$1.96 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.20 (up from US$1.96 loss in 2Q 2024). Revenue: US$1.33b (down 7.0% from 2Q 2024). Net income: US$22.9m (up US$252.8m from 2Q 2024). Profit margin: 1.7% (up from net loss in 2Q 2024). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 48 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 31Albemarle Corporation Announces Executive Changeslbemarle Corporation announced that Ander Krupa has been promoted to executive vice president, general counsel, corporate secretary, and chief compliance officer. Krupa joined Albemarle in May 2017 as vice president, deputy general counsel, and assistant corporate secretary. He has served in leadership roles supporting Albemarle's global business units, commercial activities, and mergers and acquisitions. Krupa has more than 15 years of practice in the manufacturing industry and deep experience across Albemarle's businesses. Prior to Albemarle, Krupa served as assistant general counsel, governance, and securities for BWX Technologies Inc. and The Babcock & Wilcox Company. He was also an attorney with the international law firm of Greenberg Traurig LLP in the firm's corporate and securities practice group. Krupa received a bachelor's degree from the University of Georgia and earned his J.D. from Georgia State University College of Law. He is based in the company's Charlotte, N.C., headquarters and will report to Kent Masters as part of Albemarle's executive leadership team. Krupa assumes the role following the passing in April of Albemarle's former general counsel, corporate secretary, and chief compliance officer, Stacy Grant, at which time he was named as interim general counsel.
Declared Dividend • Jul 28First quarter dividend of US$0.41 announcedDividend of US$0.41 is the same as last year. Ex-date: 12th September 2025 Payment date: 1st October 2025 Dividend yield will be 2.0%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
お知らせ • Jul 23Albemarle Corporation Declares Quarterly Common Stock Dividend, Payable on October 1, 2025The Board of Directors of Albemarle Corp. announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable October 1, 2025, to shareholders of record at the close of business as of September 12, 2025.
お知らせ • Jun 19Albemarle Corporation to Report Q2, 2025 Results on Jul 30, 2025Albemarle Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025
Upcoming Dividend • Jun 06Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 13 June 2025. Payment date: 01 July 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (4.1%).
Buy Or Sell Opportunity • May 30Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to US$55.42. The fair value is estimated to be US$70.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to decline by 1.7% in a year. Earnings are forecast to grow by 100% in the next year.
Declared Dividend • May 12First quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 13th June 2025 Payment date: 1st July 2025 Dividend yield will be 2.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
お知らせ • May 07Albemarle Announces Quarterly Common Stock Dividend, Payable on July 1, 2025The Board of Directors of Albemarle Corp. announced that it declared a quarterly common stock dividend of $0.405 per share. This marks Albemarle's 126th consecutive quarterly cash dividend. The dividend, which has an annualized rate of $1.62, is payable July 1, 2025, to shareholders of record at the close of business as of June 13, 2025.
Reported Earnings • May 01First quarter 2025 earnings released: US$0.003 loss per share (vs US$0.078 loss in 1Q 2024)First quarter 2025 results: US$0.003 loss per share (improved from US$0.078 loss in 1Q 2024). Revenue: US$1.08b (down 21% from 1Q 2024). Net loss: US$340.0k (loss narrowed 96% from 1Q 2024). Profit margin: 0% (up from net loss in 1Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 27 percentage points per year, which is a significant difference in performance.
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change).
お知らせ • Apr 03Albemarle Corporation to Report Q1, 2025 Results on Apr 30, 2025Albemarle Corporation announced that they will report Q1, 2025 results After-Market on Apr 30, 2025
お知らせ • Mar 29Albemarle Corporation, Annual General Meeting, May 06, 2025Albemarle Corporation, Annual General Meeting, May 06, 2025. Location: 4250 congress street, nc 28209, charlotte, United States
お知らせ • Mar 24Albemarle Corporation(NYSE:ALB) dropped from FTSE All-World Index (USD)Albemarle Corporation(NYSE:ALB) dropped from FTSE All-World Index (USD)
Declared Dividend • Mar 02Fourth quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 14th March 2025 Payment date: 1st April 2025 Dividend yield will be 2.1%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
お知らせ • Feb 28Albemarle Corporation Announces Quarterly Common Stock Dividend, Payable on April 1, 2025The Board of Directors of Albemarle Corporation announced that it declared a quarterly common stock dividend of $0.405 per share. The dividend, which has an annualized rate of $1.62, is payable April 1, 2025, to shareholders of record at the close of business as of March 14, 2025.
Reported Earnings • Feb 13Full year 2024 earnings released: US$11.20 loss per share (vs US$13.41 profit in FY 2023)Full year 2024 results: US$11.20 loss per share (down from US$13.41 profit in FY 2023). Revenue: US$5.38b (down 44% from FY 2023). Net loss: US$1.32b (down 184% from profit in FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.
New Risk • Feb 10New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change).
お知らせ • Jan 10Albemarle Corporation to Report Q4, 2024 Results on Feb 12, 2025Albemarle Corporation announced that they will report Q4, 2024 results After-Market on Feb 12, 2025
Recent Insider Transactions • Dec 08Chairman recently sold US$255k worth of stockOn the 5th of December, Jerry Masters sold around 3k shares on-market at roughly US$101 per share. This transaction amounted to 3.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jerry's only on-market trade for the last 12 months.
Upcoming Dividend • Dec 06Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 13 December 2024. Payment date: 02 January 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (3.8%).
Reported Earnings • Nov 07Third quarter 2024 earnings released: US$9.45 loss per share (vs US$2.58 profit in 3Q 2023)Third quarter 2024 results: US$9.45 loss per share (down from US$2.58 profit in 3Q 2023). Revenue: US$1.35b (down 41% from 3Q 2023). Net loss: US$1.11b (down 467% from profit in 3Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.
Declared Dividend • Nov 04Second quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 13th December 2024 Payment date: 2nd January 2025 Dividend yield will be 1.6%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 3.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
お知らせ • Oct 07Albemarle Corporation Announces Executive ChangesAlbemarle Corporation announced the company’s new operating structure to adapt to dynamic market conditions. As part of this change, effective Nov. 1, 2024: Specialties Business President Netha Johnson will become chief operations officer and continues to report to Chairman and CEO Kent Masters. In this role, he will lead global manufacturing, research and technology, capital projects and process chemistry execution. Johnson joined Albemarle in 2018 and has more than 25 years of experience in global manufacturing, leadership and general management. Energy Storage Business President Eric Norris will become chief commercial officer and continues to report to Masters. In this role, he will oversee enterprise product management, sales and commercial excellence. Norris joined Albemarle in 2018 and has more than 25 years of experience in strategy, corporate development and general management. In addition, the following leaders will report to Masters: Melissa Anderson will become chief transformation officer, effective Nov. 1, which reflects her current oversight of people, strategy and transformation; Stacy Grant will become general counsel, corporate secretary and chief compliance officer, effective immediately, and succeeds Kristin Coleman, who is leaving the company. Grant joined Albemarle in 2023 and previously served as vice president & deputy general counsel, global corporate affairs; Mark Mummert will become chief capital, resources and integrated supply chain officer, effective Nov. 1, which includes expanded responsibility for resources, joint venture management, customer service and operational excellence. On October 7, 2024, in connection with the implementation of the new operating structure described in Item 7.01 below, Kristin Coleman will cease serving as Executive Vice President, General Counsel and Corporate Secretary of the Company and her last day of employment will be November 4, 2024. In addition, in connection with the implementation of such new operating structure, John C. Barichivich III will cease serving as Vice President, Corporate Controller and Chief Accounting Officer of the company effective upon the appointment of his successor, and his last day of employment will be December 31, 2024.
お知らせ • Oct 01Albemarle Corporation to Report Q3, 2024 Results on Nov 06, 2024Albemarle Corporation announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
Upcoming Dividend • Sep 06Upcoming dividend of US$0.41 per shareEligible shareholders must have bought the stock before 13 September 2024. Payment date: 01 October 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.5%). Lower than average of industry peers (3.3%).
New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
お知らせ • Aug 13Albemarle Reportedly May Look to Offload 49% Stake in Greenbushes Lithium Mine to IGOSpeculation is mounting that US-based Albemarle Corporation (NYSE:ALB) may be considering selling down its 49% stake in the Greenbushes lithium mine to its Australian-listed partner IGO Limited (ASX:IGO), after the world's largest lithium producer this month slashed jobs and shut part of a processing facility in Western Australia. Greenbushes in WA is a global standout, and there is scepticism about the market chatter, although IGO wants to buy more of the asset should it be available, say sources. IGO did not comment. One reason a sale may be on the table is that Greenbushes does not qualify for the Inflation Reduction Act benefits in the US because of its partial Chinese ownership of 25.1%. To quality, Chinese ownership would need to be 24.9% or less, although the US government may show some leniency. IGO and China's Tianqi both own 51% in a joint venture arrangement. US-based lithium specialist Albemarle owns the remainder. The Australian reported last month that Albemarle, Tianqi and IGO would be taking the brakes off the giant Greenbushes mine despite low lithium prices, with the mine set to lift production over the next year as IGO intensifies its hunt for growth opportunities.
Reported Earnings • Aug 01Second quarter 2024 earnings released: US$1.96 loss per share (vs US$5.54 profit in 2Q 2023)Second quarter 2024 results: US$1.96 loss per share (down from US$5.54 profit in 2Q 2023). Revenue: US$1.43b (down 40% from 2Q 2023). Net loss: US$229.9m (down 135% from profit in 2Q 2023). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Declared Dividend • Jul 19First quarter dividend of US$0.41 announcedShareholders will receive a dividend of US$0.41. Ex-date: 13th September 2024 Payment date: 1st October 2024 Dividend yield will be 1.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 191% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jul 02Albemarle Corporation to Report Q2, 2024 Results on Jul 31, 2024Albemarle Corporation announced that they will report Q2, 2024 results After-Market on Jul 31, 2024
Upcoming Dividend • Jun 07Upcoming dividend of US$0.40 per shareEligible shareholders must have bought the stock before 14 June 2024. Payment date: 01 July 2024. Payout ratio is a comfortable 58% but the company is not cash flow positive. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (3.1%).
Declared Dividend • May 12First quarter dividend of US$0.40 announcedDividend of US$0.40 is the same as last year. Ex-date: 14th June 2024 Payment date: 1st July 2024 Dividend yield will be 1.2%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (58% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 186% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 03Albemarle Corporation Reaffirms Earnings Guidance for the Year 2024Albemarle Corporation reaffirmed earnings guidance for the year 2024. For the period, the company expects net sales of $5.5 billion to $6.2 billion.
Reported Earnings • May 02First quarter 2024 earnings released: US$0.078 loss per share (vs US$10.57 profit in 1Q 2023)First quarter 2024 results: US$0.078 loss per share (down from US$10.57 profit in 1Q 2023). Revenue: US$1.36b (down 47% from 1Q 2023). Net loss: US$9.14m (down 101% from profit in 1Q 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Apr 07Albemarle Corporation to Report Q1, 2024 Results on May 01, 2024Albemarle Corporation announced that they will report Q1, 2024 results After-Market on May 01, 2024
お知らせ • Mar 13Albemarle Corporation, Annual General Meeting, May 07, 2024Albemarle Corporation, Annual General Meeting, May 07, 2024, at 07:00 Eastern Standard Time. Location: Albemarle Corporation, 4250 Congress Street, Charlotte, North Carolina 28209, Charlotte North Carolina United States Agenda: To consider and Elect the ten nominees; to approve, on a non-binding advisory basis, the compensation of named executive officers; to approve an amendment to Albemarle's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock; to ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.
Upcoming Dividend • Mar 07Upcoming dividend of US$0.40 per shareEligible shareholders must have bought the stock before 14 March 2024. Payment date: 01 April 2024. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of British dividend payers (6.3%). Lower than average of industry peers (3.1%).
Valuation Update With 7 Day Price Move • Mar 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to US$138, the stock trades at a forward P/E ratio of 21x. Average trailing P/E is 17x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 2.5% over the past three years.
Declared Dividend • Feb 25Fourth quarter dividend of US$0.40 announcedDividend of US$0.40 is the same as last year. Ex-date: 14th March 2024 Payment date: 1st April 2024 Dividend yield will be 1.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 16Full year 2023 earnings released: EPS: US$13.41 (vs US$22.97 in FY 2022)Full year 2023 results: EPS: US$13.41 (down from US$22.97 in FY 2022). Revenue: US$9.62b (up 31% from FY 2022). Net income: US$1.57b (down 42% from FY 2022). Profit margin: 16% (down from 37% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Jan 19Albemarle Reportedly Selling Out of LiontownAlbemarle Corporation (NYSE:ALB) has appointed brokers to sell its stake in Liontown Resources Limited (ASX:LTR), three months after Hancock Prospecting effectively blocked its $6.6 billion takeover bid. JP Morgan was looking to sell Albemarle's 4% stake after the market closed, at prices ranging from $1.26 per share to $1.32 per share. With Albemarle holding 96 million Liontown shares, the deal will be worth about $125 million. The planned sale will be at a loss for Albemarle, which was understood to have acquired its stake at an average entry price of $2.35 per share. Albemarle attempted four times to acquire Liontown, which is developing the Kathleen Valley lithium mine in the Goldfields. The mine would have provided a new supply for Albemarle's downstream processing operations, including its lithium refinery at Kemerton in the South West. It lodged indicative proposals at $2.20 per share in October 2022, $2.35 in March 2023 and $2.50 later that month. It appeared to have succeeded in September when the Liontown board backed its fourth proposal - a takeover bid priced at $3 per share. However Australia's richest person, Gina Rinehart, ended the party after her private company Hancock Prospecting acquired a 19.9% blocking stake. Albemarle scrapped its takeover bid in mid-October, triggering a collapse in Liontown's share price and forcing the company to complete an equity and debt raising to ensure it could complete construction at Kathleen Valley. Hancock has retained its 19.9% stake but has been silent on its intentions.
お知らせ • Jan 12Albemarle Corporation to Report Q4, 2023 Results on Feb 14, 2024Albemarle Corporation announced that they will report Q4, 2023 results After-Market on Feb 14, 2024
Upcoming Dividend • Dec 07Upcoming dividend of US$0.40 per share at 1.4% yieldEligible shareholders must have bought the stock before 14 December 2023. Payment date: 02 January 2024. Payout ratio is a comfortable 5.6% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (3.2%).
New Risk • Nov 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (27% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).
お知らせ • Nov 18Albemarle Corporation Announces the Promotion of Cynthia Lima as Senior Vice President, Chief External Affairs and Communications OfficerAlbemarle Corporation announced that Cynthia Lima has been promoted to senior vice president, chief external affairs and communications officer. Lima joined Albemarle early in 2023 as chief communications officer and has expanded her remit to include the global external affairs function. She brings extensive government affairs and communications experience spanning both public and private sectors. Prior to joining Albemarle, Lima founded a communications and public affairs consultancy and held senior positions at domestic and global public relations agencies. Previously, Lima served in the U.S. Department of State and U.S. Department of Veterans Affairs where she was a senate-confirmed presidential appointee. Lima is based in the company's Charlotte, N.C., headquarters and will report to Masters as part of Albemarle's Executive Leadership Team.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$2.58 (vs US$7.66 in 3Q 2022)Third quarter 2023 results: EPS: US$2.58 (down from US$7.66 in 3Q 2022). Revenue: US$2.31b (up 11% from 3Q 2022). Net income: US$302.5m (down 66% from 3Q 2022). Profit margin: 13% (down from 43% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 02Albemarle Corporation Revises Net Sales Guidance for the Full Year 2023Albemarle Corporation revised net sales guidance for the full year 2023. For the year, the company now expects net sales to be in the range of $9.5 billion to $9.8 billion against previous guidance of $10.4 billion to $11.5 billion.
お知らせ • Oct 28Albemarle Corporation Announces CFO Changes, Effective on November 6, 2023Albemarle Corporation announced that Neal Sheorey will join Albemarle as its chief financial officer, effective Nov. 6, 2023. Scott Tozier, Albemarle's current chief financial officer, will transition from his current role and become a strategic advisor to the CEO. Sheorey joins Albemarle from Dow, a global materials science company, where he served for more than 20 years in progressive finance, business, and corporate leadership roles. Most recently, he was vice president of Dow's Coatings & Performance Monomers business unit, a global portfolio with more than $4 billion in sales, where he was responsible for the group's strategy, profitability, and growth initiatives. Prior to his current role, Sheorey served as Dow's vice president of investor relations, senior director of corporate development and global finance director for the Chemicals business group. Sheorey holds a master's degree in business administration with a concentration in finance and corporate strategy from the University of Michigan, and a bachelor's degree in chemical engineering from Northwestern University. Tozier joined Albemarle in 2011 as senior vice president and chief financial officer.
お知らせ • Oct 27Albemarle Corporation Announces Executive Changes, Effective on November 6, 2023Albemarle Corporation announced that Neal Sheorey will join Albemarle as its executive vice president, effective Nov. 6, 2023. Scott Tozier, Albemarle's current executive vice president will transition from his current role and become a strategic advisor to the CEO. Sheorey joins Albemarle from Dow, a global materials science company, where he served for more than 20 years in progressive finance, business, and corporate leadership roles. Most recently, he was vice president of Dow's Coatings & Performance Monomers business unit, a global portfolio with more than $4 billion in sales, where he was responsible for the group's strategy, profitability, and growth initiatives. Prior to his current role, Sheorey served as Dow's vice president of investor relations, senior director of corporate development and global finance director for the Chemicals business group. Sheorey holds a master's degree in business administration with a concentration in finance and corporate strategy from the University of Michigan, and a bachelor's degree in chemical engineering from Northwestern University. Tozier joined Albemarle in 2011 as senior vice president and chief financial officer.
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to US$140, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 53% over the past three years.
お知らせ • Oct 20Albemarle Corporation (NYSE:ALB) completed the acquisition of additional 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources Limited (ASX:MIN)Albemarle Corporation (NYSE:ALB) entered into binding agreement to acquire additional 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources Limited (ASX:MIN) on February 23, 2023. As of July 19, 2023, Albemarle Corporation amend the terms of the transaction and agreed to acquire remaining 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources for approximately AUD 590 million ($400 million). Albemarle will supply MinRes’ 15% share of spodumene concentrate for use by Kemerton from the Greenbushes mine. MinRes will pay the benchmark price for its share of Greenbushes spodumene concentrate. In similar transaction Albemarle Corporation entered into binding agreement ownership of the Wodgina mine to change from 60% and 40% to 50% and50%. Albemarle is expected to pay MinRes a completion adjustment currently estimated to be AUD 150 million. As of July 19, 2023, upon closing, Albemarle expects to pay Mineral Resources $380 (AUD 557.5 million) - $400 million (AUD 586.9 million) which includes net consideration for the remaining 15% ownership of Kemerton as well as EED settlement adjustments. Actual settlement adjustments will depend on the date of close. The acquisition is subject to regulatory approvals. The parties anticipate closing the amended arrangements later this year. As of August 2, 2023, the transaction is expected to close in the second half of 2023. Herbert Smith Freehills LLP acted as legal advisor to Kemerton Lithium Hydroxide Plant. Albemarle Corporation (NYSE:ALB) completed the acquisition of additional 40% stake in Kemerton Lithium Hydroxide Plant from Mineral Resources Limited (ASX:MIN) on October 18, 2023.
お知らせ • Oct 16Albemarle Withdraws Non-Binding Offer to Acquire Liontown ResourcesOn October 15, 2023, Albemarle Corporation (NYSE:ALB) announced that it will not pursue a binding agreement to purchase Liontown Resources Limited (ASX:LTR) and has formally withdrawn its non-binding offer to Liontown's board of directors. The decision comes as Albemarle nears the end of its exclusive due diligence process. "Our engagement with the Liontown team has been meaningful and productive. We appreciate the level of cooperation we have received, and we thank the entire team for their efforts," said Kent Masters, Chief Executive Officer of Albemarle. "That said, moving forward with the acquisition, at this time, is not in Albemarle's best interests." The company noted growing complexities associated with the proposed transaction as a factor in its decision. The announcement is consistent with Albemarle's disciplined approach to capital allocation and the company will continue to execute its long-term growth strategy. Planned expansions to deliver volumetric growth continue to progress across the company's global portfolio. Albemarle's capital allocation priorities remain investing in high-return organic and inorganic growth, maintaining its financial flexibility and investment grade credit rating, and funding its dividends. Albemarle is one of Australia's biggest lithium investors, with mining assets at Wodgina and Greenbushes, and with the Kemerton lithium hydroxide plant, which is currently undergoing a significant expansion.
お知らせ • Oct 06Albemarle Corporation to Report Q3, 2023 Results on Nov 01, 2023Albemarle Corporation announced that they will report Q3, 2023 results After-Market on Nov 01, 2023
Upcoming Dividend • Sep 07Upcoming dividend of US$0.40 per share at 0.8% yieldEligible shareholders must have bought the stock before 14 September 2023. Payment date: 02 October 2023. Payout ratio is a comfortable 4.8% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of British dividend payers (6.3%). Lower than average of industry peers (2.8%).
お知らせ • Sep 06Albemarle Makes Another Sweetened Bid for LiontownRecently rejected suitor, US specialty chemicals firm Albemarle Corporation (NYSE:ALB) has tabled a sweetened bid to acquire Australian lithium start-up Liontown Resources Limited (ASX:LTR) in a deal valuing the target company at about AUD 6.6 billion (USD 4.26 billion/EUR 3.95 billion). Albemarle’s new, conditional and non-binding indicative proposal provides for each Liontown share to be exchanged for AUD 3.00 apiece. It is Albemarle’s best and final proposal, in the absence of a superior proposal, according to a statement from September 4, 2023. The Australian firm said that its board has determined to grant Albemarle an opportunity to conduct a limited period of exclusive due diligence, subject to customary fiduciary exceptions, to enable it to put forward a binding proposal. Liontown at the end of March turned down an improved AUD-5.5-billion takeover bid from Albemarle considering the offer substantially under-priced. The previous bid implied a consideration of AUD 2.50 per Liontown share.
お知らせ • Aug 04Albemarle Corporation Revises Earnings Guidance for the Fiscal Year 2023Albemarle Corporation revised earnings guidance for the fiscal year 2023. For the fiscal, the company expects net sales of $10.4 billion - $11.5 billion from previous guidance of $9.8 - $11.5 billion.
New Risk • Aug 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. High level of non-cash earnings (29% accrual ratio).
Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: US$5.54 (vs US$3.47 in 2Q 2022)Second quarter 2023 results: EPS: US$5.54 (up from US$3.47 in 2Q 2022). Revenue: US$2.37b (up 60% from 2Q 2022). Net income: US$650.0m (up 60% from 2Q 2022). Profit margin: 27% (in line with 2Q 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 12Albemarle Corporation to Report Q2, 2023 Results on Aug 02, 2023Albemarle Corporation announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2023
お知らせ • Jun 25Albemarle Corporation(NYSE:ALB) dropped from Russell 1000 Growth IndexAlbemarle Corporation(NYSE:ALB) dropped from Russell 1000 Growth Index
Upcoming Dividend • Jun 08Upcoming dividend of US$0.40 per share at 0.7% yieldEligible shareholders must have bought the stock before 15 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 5.1% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.5%).
Recent Insider Transactions • May 16President of Albemarle Energy Storage recently bought US$246k worth of stockOn the 10th of May, Eric Norris bought around 1k shares on-market at roughly US$195 per share. This transaction amounted to 5.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth US$994k. Despite this recent purchase, insiders have collectively sold US$3.1m more in shares than they bought in the last 12 months.
Recent Insider Transactions • May 09Chairman & CEO recently bought US$994k worth of stockOn the 5th of May, Jerry Masters bought around 5k shares on-market at roughly US$182 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jerry's only on-market trade for the last 12 months.
お知らせ • May 05Albemarle Corporation Revises Earnings Guidance for the Full Year 2023Albemarle Corporation revised earnings guidance for the full year 2023. For the year, the company’s net sales are expected to increase 35% to 55% over prior year, primarily driven by a continued global shift to electric vehicles. Net sales are now expected to be in the range of $9.8 billion to $11.5 billion compared to previous guidance of $11.3 billion to $12.9 billion.
Reported Earnings • May 04First quarter 2023 earnings released: EPS: US$10.57 (vs US$2.16 in 1Q 2022)First quarter 2023 results: EPS: US$10.57 (up from US$2.16 in 1Q 2022). Revenue: US$2.58b (up 129% from 1Q 2022). Net income: US$1.24b (up 389% from 1Q 2022). Profit margin: 48% (up from 23% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$174, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 208% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$328 per share.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to US$212, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 12x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 230% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$356 per share.
Upcoming Dividend • Mar 09Upcoming dividend of US$0.40 per share at 0.6% yieldEligible shareholders must have bought the stock before 16 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 6.9% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (3.0%).
Buying Opportunity • Feb 18Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 7.7%. The fair value is estimated to be US$336, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 51%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 1.1% per annum over the same time period.
Reported Earnings • Feb 17Full year 2022 earnings released: EPS: US$22.97 (vs US$1.07 in FY 2021)Full year 2022 results: EPS: US$22.97 (up from US$1.07 in FY 2021). Revenue: US$7.32b (up 120% from FY 2021). Net income: US$2.69b (up US$2.57b from FY 2021). Profit margin: 37% (up from 3.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to US$278, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 257% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$318 per share.
お知らせ • Jan 24Albemarle Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 and Full Year of 2023Albemarle Corporation provides revenue guidance for the fourth quarter and full year ended December 31, 2022 and full year of 2023. For the quarter of 2022, company expects Net sales of between $2,590 million and $2,650 million, up 190% to 196%, Net income in the range of $1,107 million to $1,157 million and Diluted EPS of between $9.30 and $9.80. For the year of 2022, company expects Net sales of between $7,290 million - $7,350 million, Net income (loss) attributable to Albemarle Corporation $2,662 million - $2,712 million and Diluted earnings (loss) per share $22.50 - $23.00. For the year of 2023, company expects Net sales of $11.3 billion - $12.9 billion.
お知らせ • Jan 18Albemarle Corporation to Report Q4, 2022 Results on Feb 15, 2023Albemarle Corporation announced that they will report Q4, 2022 results After-Market on Feb 15, 2023
Buying Opportunity • Jan 10Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be US$277, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 7.0%. For the next 3 years, revenue is forecast to grow by 9.4% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.
